Concert Pharmaceuticals Inc.

4.25-0.1600-3.63%Vol 81.77K1Y Perf -58.36%
Apr 19th, 2021 10:35 DELAYED
BID4.23 ASK4.25
Open4.41 Previous Close4.41
Pre-Market4.31 After-Market-
 -0.10 -2.27%  - -
Target Price
19.00 
Analyst Rating
Strong Buy 1.40
Potential %
348.11 
Finscreener Ranking
★★★★     55.51
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★★     56.02
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★+     50.77
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap136.74M 
Earnings Rating
Sell
Price Range Ratio 52W %
0.22 
Earnings Date
29th Apr 2021

Today's Price Range

4.234.49

52W Range

4.2313.50

5 Year PE Ratio Range

-3.8020.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-3.50%
1 Month
-29.78%
3 Months
-62.78%
6 Months
-61.92%
1 Year
-58.36%
3 Years
-78.13%
5 Years
-67.50%
10 Years
-

TickerPriceChg.Chg.%
CNCE4.25-0.1600-3.63
AAPL135.120.96000.72
GOOG2 301.924.16000.18
MSFT260.01-0.7300-0.28
XOM56.57-0.0900-0.16
WFC44.360.52001.19
JNJ162.23-0.0100-0.01
FB304.29-1.8900-0.62
GE13.34-0.0500-0.37
JPM153.16-0.1400-0.09
Financial StrengthValueIndustryS&P 500US Markets
13.30
14.00
0.10
0.12
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-911.70
-891.20
-7 563.70
-
RevenueValueIndustryS&P 500US Markets
7.90M
0.25
-67.35
-19.80
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.73-0.695.48
Q03 2020-0.68-0.6011.76
Q02 2020-0.68-0.4139.71
Q01 2020-0.74-0.705.41
Q04 2019-0.78-0.86-10.26
Q03 2019-0.85-0.7215.29
Q02 2019-0.92-0.7815.22
Q01 2019-0.62-0.93-50.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.66-8.20Negative
6/2021 QR-0.67-6.35Negative
12/2021 FY-2.57-1.58Negative
12/2022 FY-2.30-15.58Negative
Next Report Date29th Apr 2021
Estimated EPS Next Report-0.66
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume81.77K
Shares Outstanding32.17M
Trades Count459
Dollar Volume2.63M
Avg. Volume475.86K
Avg. Weekly Volume187.48K
Avg. Monthly Volume414.96K
Avg. Quarterly Volume524.40K

Concert Pharmaceuticals Inc. (NASDAQ: CNCE) stock closed at 4.41 per share at the end of the most recent trading day (a -4.55% change compared to the prior day closing price) with a volume of 313.64K shares and market capitalization of 136.74M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 71 people. Concert Pharmaceuticals Inc. CEO is Roger D. Tung.

The one-year performance of Concert Pharmaceuticals Inc. stock is -58.36%, while year-to-date (YTD) performance is -65.11%. CNCE stock has a five-year performance of -67.5%. Its 52-week range is between 4.23 and 13.5, which gives CNCE stock a 52-week price range ratio of 0.22%

Concert Pharmaceuticals Inc. currently has a PE ratio of -1.90, a price-to-book (PB) ratio of 1.13, a price-to-sale (PS) ratio of 18.62, a price to cashflow ratio of 3.40, a PEG ratio of 2.32, a ROA of -48.40%, a ROC of -52.08% and a ROE of -61.89%. The company’s profit margin is -%, its EBITDA margin is -891.20%, and its revenue ttm is $7.90 Million , which makes it $0.25 revenue per share.

Of the last four earnings reports from Concert Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.66 for the next earnings report. Concert Pharmaceuticals Inc.’s next earnings report date is 29th Apr 2021.

The consensus rating of Wall Street analysts for Concert Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $19, which is +348.11% compared to the current price. The earnings rating for Concert Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Concert Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Concert Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 27.96, ATR14 : 0.47, CCI20 : -107.78, Chaikin Money Flow : -0.25, MACD : -1.03, Money Flow Index : 57.82, ROC : -9.26, RSI : 31.27, STOCH (14,3) : 7.56, STOCH RSI : 0.56, UO : 37.56, Williams %R : -92.44), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Concert Pharmaceuticals Inc. in the last 12-months were: James V. Cassella (Sold 4 354 shares of value $45 151 ), Marc E. Becker (Sold 2 875 shares of value $29 440 ), Nancy Stuart (Option Excercise at a value of $80 492), Nancy Stuart (Sold 10 295 shares of value $116 694 ), Peter Barton Hutt (Option Excercise at a value of $13 413)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
5 (83.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (20.00 %)
1 (20.00 %)
1 (16.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.40
Strong Buy
1.33

Concert Pharmaceuticals Inc.

Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the current approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.

CEO: Roger D. Tung

Telephone: +1 781 860-0045

Address: 65 Hayden Avenue, Lexington 02421, MA, US

Number of employees: 71

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

79%21%

Bearish Bullish

44%56%

Bearish Bullish

50%50%

News

Stocktwits